Bladder Cancer
‘A call to arms’: Addressing the undertreatment of advanced bladder cancer
For decades, the 5-year survival rate for patients with advanced bladder cancer has remained at about 35%.
Avelumab maintenance extends OS in advanced urothelial carcinoma
Avelumab switch maintenance prolonged OS among patients with advanced urothelial carcinoma whose disease did not progress after first-line chemotherapy, according to study results presented during the ASCO20 Virtual Scientific Program.
Blood test detects dozens of cancer types, often before symptoms emerge
A novel blood test accurately detected more than 50 types of cancer with a specificity of 99.3%, according to results of the prospective Circulating Cell-free Genome Atlas study published in Annals of Oncology.
Phase 3 trial evaluating two bladder cancer regimens fails to meet key endpoints
A randomized phase 3 trial designed to evaluate two experimental first-line treatment approaches for patients with advanced bladder cancer failed to meet its primary endpoints.
FDA grants breakthrough therapy designation to Padcev regimen for advanced bladder cancer
The FDA granted breakthrough therapy designation to enfortumab vedotin-ejfv in combination with pembrolizumab for the treatment of patients with unresectable locally advanced or metastatic urothelial cancer who are ineligible for first-line cisplatin-based chemotherapy, according to a press release from the agent’s manufacturer.
Phase 3 trial of atezolizumab for urothelial cancer misses primary endpoint
Adjuvant atezolizumab failed to extend DFS compared with observation among patients with muscle-invasive urothelial cancer, according to topline results of a randomized phase 3 trial released by the agent’s manufacturer.
FDA approves Keytruda for bladder cancer subset
Cancer survivors may have increased CVD mortality risk
Patients who survived cancer have an increased risk for mortality from CHD and stroke compared with the general population, according to a study published in the European Heart Journal.
Sustained weight loss protects against breast cancer, FDA supports another indication for Keytruda — top stories in hematology/oncology
A recent study showed that women aged 50 years and older with sustained weight loss for longer than 8 years had a decreased risk for breast cancer — giving clinicians even more reason to recommend that their patients lose weight and keep it off. This was one of the top stories last week in hematology/oncology.
FDA advisory committee supports approval of Keytruda for high-risk bladder cancer
An FDA advisory committee today voted to support approval of pembrolizumab for the treatment of patients with bacillus Calmette-Guérin-unresponsive, high-risk, nonmuscle-invasive bladder cancer with carcinoma in-situ with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy.